Chronic Leukemia Information

Advances in the Management of Chronic Myeloid Leukemia (CML): A Report from the 2007 American Society of Hematology (ASH) Meeting
Hagop M. Kantarjian, MD, Chairman & Professor, Leukemia Department University of Texas M. D. Anderson Cancer Center, Houston, Texas

Expert Interview: Updates in the Management of Chronic Myeloid Leukemia from ASH 2007
Hagop M. Kantarjian, MD, Chairman & Professor, Leukemia Department University of Texas M. D. Anderson Cancer Center, Houston, Texas

Flavopiridol Confirmed Active for Treatment of Relapsed CLL with Adverse Cytogenetics (1/2/2009)
Researchers from Ohio State University have reported that flavopiridol produces durable responses in patients with relapsed chronic lymphocytic leukemia (CLL) with high-risk cytogenetic abnormalities. The details of this study were presented at the 2008 meeting of the American Society of Hematology on December 7, 2008 in San Francisco.

Fostamatinib Disodium Effective for Diffuse B-Cell Lymphoma and CLL (12/17/2008)
Researcher involved in a U.S. multicenter trial have reported that the oral inhibitor of spleen tyrosine kinase (SYK), Fosamatinib disodium (FosD) (R788), has significant activity and is well tolerated in patients with diffuse large B cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL). The results of this phase 1-2 study were reported in the Plenary Session of the 50^th annual meeting of the American Society of Hematology on December 7, 2008 in San Francisco.

Treanda® and Rituxan® Effective for Relapsed CLL (12/10/2008)
Researchers affiliated with the German CLL Study Group have reported that Treanda® (bendamustine) and Rituxan® (rituximab) is an effective regimen for patients with relapsed chronic lymphocytic leukemia (CLL). The details of this study were presented at the annual meeting of the American Society of Hematology on December 8, 2008 in San Francisco.

Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, Effecitive in CLL (12/10/2008)
Researchers involved in an International Phase II study have reported that Ofatumumab, a human Anti-CD20 monoclonal antibody, is effective for the treatment of patients with chronic lymphocytic leukemia (CLL) who have failed Fludara® (fludarabine) and Campath® (alemtuzumab) or who had failed Fludara and had bulky disease. The details of this study were presented at the annual meeting of the American Society of Hematology on December 8, 2008 in San Francisco.

Rituxan® and High-dose Methylprednisolone Effective Initial Treatment of CLL (12/9/2008)
Researchers from the University of California at San Diego (UCSD) have reported that the combination of Rituxan® (rituximab) and high-dose methylpredisolone is “an effective non-myelotoxic treatment regimen for patients with chronic lymphocytic leukemia (CLL).” The details of this Phase II study were presented at the annual meeting of the American Society of Hematology on December 7, 2008 in San Francisco.